Tahrani, Abd A.
Barnett, Anthony H.
Bailey, Clifford J.
Article History
First Online: 24 June 2016
Competing interests
: A.A.T. is a clinician scientist supported by the National Institute for Health Research (NIHR) in the UK. The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health. A.A.T. has received honoraria for lectures and advisory work or support for attending conferences from Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk and Sanofi-Aventis. A.A.T. received investigator-led grant support from the Novo Nordisk Research Foundation. A.H.B. has received honoraria for lectures and advisory work from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, MSD, Novartis, Novo Nordisk, Sanofi-Aventis and Takeda. C.J.B. has undertaken ad-hoc consultancy for AstraZeneca, Bristol-Myers Squibb, Elcelyx, Eli Lilly, Janssen, Lexicon, MSD, Novo Nordisk, Roche, Sanofi-Aventis and Takeda. C.J.B. has delivered continuing medical education programmes sponsored by AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and MSD, and received travel or accommodation reimbursement from AstraZeneca and Bristol-Myers Squibb.